Production (Stage)
NLS Pharmaceutics AG
NLSP
$2.30
$0.2210.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 0.00% | 102.70% | 0.00% | 55.35% | 0.00% |
| Total Depreciation and Amortization | 0.00% | -141.38% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.00% | -2,582.49% | 0.00% | -44.59% | 0.00% |
| Change in Net Operating Assets | 0.00% | -180.61% | 0.00% | -79.85% | 0.00% |
| Cash from Operations | 0.00% | -78.87% | 0.00% | 35.91% | 0.00% |
| Capital Expenditure | 0.00% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00% | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | 0.00% |
| Total Debt Repaid | 0.00% | 200.00% | 0.00% | -- | -- |
| Issuance of Common Stock | 0.00% | 193.12% | 0.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | -- | -- | -- | -- |
| Cash from Financing | 0.00% | 225.07% | 0.00% | -27.43% | 0.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | 0.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.00% | 422.49% | 0.00% | 54.23% | 0.00% |